Science ❯ Biotechnology

Drug Development

Clinical Trials Clinical Research Oncology Formulation Science Regulatory Affairs Cancer Research Cancer Treatments Biomacromolecules Artificial Intelligence Integrated Stress Response Manufacturing Lifespan Extension Autoimmune Conditions ANAVEX®2-73 Mechanism of Action Phase 2 Studies Biosimilars Peptide Synthesis Analytical Techniques Nanoparticle Formulation Preclinical Testing Nanotechnology RNA Interference Market Trends Therapeutic Interventions Targeted Therapies Clinical Studies Research and Development Smart Insulin Non-Pharmaceutical Interventions Therapeutic Innovations Cancer Therapies Therapeutic Candidates

Olema Soars on Roche SERD Win, Then Slips on Planned Stock Offering

Investor enthusiasm cooled after Olema moved to raise capital, heightening dilution concerns.

myTomorrows Raises $29 Million From Avego to Scale AI Platform for Pre-Approval Treatments

MIT's Timed Drug-Release Heart Patch Halves Damage in Rat Heart Attacks

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline

FDA Accepts Replimune’s Resubmitted RP1 Melanoma Filing, Sets April 2026 Decision

Tubulis Raises €308 Million Series C to Accelerate Lead Cancer ADC

Novo Nordisk to Acquire Akero for Up to $5.2 Billion to Expand in MASH

Genmab to Buy Merus for $8 Billion to Secure Petosemtamab Cancer Drug

Terasaki Researchers Debut Human Liver Tumor ‘Embolization-on-a-Chip’ for Embolic Therapy Testing

Penn Team Debuts AMP‑Diffusion, an AI That Designs Antibiotic Peptides Effective in Mice

Stanford Spray-Drying Method Could Turn Many IV Biologics Into Quick Injections

FDA Names George Tidmarsh Director of Center for Drug Evaluation and Research

Weekly Parkinson’s Injection Secures Patent After Successful Lab Trials

Merck to Acquire Verona Pharma in $10 Billion Deal for Ohtuvayre COPD Therapy

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline

Sanofi to Acquire Vigil Neuroscience in $600M Deal to Advance Alzheimer’s Research